SCHEMBL3408440

SCHEMBL3408440

OC1CCN(c2ccnc(Cl)n2)CC1

nearest known ligand 0.58

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 11/20 0.49
SORD Q00796 2/20 0.48
HRH3 Q9Y5N1 1/20 0.47
SMPD3 Q9NY59 1/20 0.43
PTPN11 Q06124 1/20 0.43
CCNT1 O60563 1/20 0.42
OGA O60502 1/20 0.41
SMO Q99835 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29074751 0.90 TRPV1 (0.44) TRPV1SORDHRH3
SCHEMBL31402770 0.90 TRPV1 (0.44) TRPV1SORDHRH3
SCHEMBL786734 0.83 OGA (0.51) TRPV1SORDHRH3OGA
SCHEMBL3964095 0.83 HRH3 (0.69) TRPV1SORDHRH3PTPN11OGA
SCHEMBL1427771 0.83 TRPV1 (0.45) TRPV1SORD
SCHEMBL4749195 0.83 SORD (0.51) TRPV1SORDHRH3
Hydrochloric Acid SCHEMBL2276239 0.82 HRH3 (0.67) TRPV1SORDHRH3PTPN11OGA
SCHEMBL14810701 0.81 LMNA (0.57) TRPV1SORD
SCHEMBL20445954 0.81 SMPD3 (0.48) TRPV1SORDSMPD3
SCHEMBL15241209 0.81 CCR4 (0.43) TRPV1SORDHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4746911-A1 PHOSPHORAMIDITE LINKERS United Kingdom Research and Innovation (GB) 2026-05-27 EP disclosed
WO-2025021654-A1 PHOSPHORAMIDITE LINKERS UNITED KINGDOM RESEARCH AND INNOVATION (GB) 2025-01-30 WO disclosed
EP-2300465-B1 IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES ASTEX THERAPEUTICS LTD (GB) 2019-04-17 EP disclosed
US-8962834-B2 Modulators of amyloid beta HOFFMANN-LA ROCHE INC. (US) 2015-02-24 US disclosed
US-8796244-B2 Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases ASTEX THERAPEUTICS LTD (GB) 2014-08-05 US disclosed
EP-2257541-B1 MODULATORS FOR AMYLOID BETA HOFFMANN LA ROCHE (CH) 2013-08-14 EP disclosed
US-20130190302-A1 MODULATORS OF AMYLOID BETA HOFFMANN-LA ROCHE INC. (US) 2013-07-25 US disclosed
US-20120208791-A1 IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES ASTEX THERAPEUTICS LIMITED (GB) 2012-08-16 US disclosed
CN-101952275-A Modulators for amyloid beta HOFFMANN LA ROCHE 2011-01-19 CN disclosed
EP-2257541-A1 MODULATORS FOR AMYLOID BETA F. Hoffmann-La Roche AG (CH) 2010-12-08 EP disclosed
US-20090215759-A1 MODULATORS FOR AMYLOID BETA HOFFMANN-LA ROCHE, INC. 2009-08-27 US disclosed
WO-2009103652-A1 MODULATORS FOR AMYLOID BETA F. HOFFMANN-LA ROCHE AG (CH) 2009-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208791-A1 IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES ABL1, ERBB2, RET TRPV1 658/4885SORD 3207/4885HRH3 712/4885
US-20090215759-A1 MODULATORS FOR AMYLOID BETA APP, PSEN1, APOB TRPV1 3240/4885SORD 425/4885HRH3 1365/4885
US-20130190302-A1 MODULATORS OF AMYLOID BETA APP, PSEN1, APOB TRPV1 3275/4885SORD 415/4885HRH3 1442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.